RXRA and cancer: For example, epoxinnamide (2) exhibited antiangiogenesis activity, dentigerumycin E (9) showed antiproliferative and antimetastatic potential, nobilamide I (10) decreased cancer cell motility by inhibiting EMT effectors, ectyoplasin (39) was responsible for apoptotic cell death, phakefustatin A (40) was identified as a RXRα modulator, and asperflomide (28) and asperflosamide (29) showed inhibition of tankyrase1/2.